Pindolol does not augment central serotonin function increases to citalopram in humans: An auditory evoked potential investigation

Pharmacology Biochemistry and Behavior

Volumn 85, Issue 1, 2006, Pages 82-90

  Segrave, Rebecca ^a   Croft, Rodney J ^a,c   Illic, Susan ^a   Luan Phan, K ^b,c   Nathan, Pradeep J ^c  

^a SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^b UNIVERSITY OF CHICAGO   (United States)

^c Behavioural Neuroscience Laboratory   (Australia)

Author keywords

5 HT1A receptor; Citalopram; Loudness dependence auditory evoked potentials; Pindolol; Selective serotonin reuptake inhibitor; Serotonin

Indexed keywords

CITALOPRAM; PINDOLOL; SEROTONIN;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; EVOKED AUDITORY RESPONSE; FEMALE; HUMAN; LOUDNESS; MALE; NORMAL HUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

ADULT; CITALOPRAM; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, AUDITORY; FEMALE; HUMANS; MALE; PINDOLOL; PLACEBOS; SEROTONIN;

ANIMALIA;

EID: 33751120957     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2006.07.013     Document Type: Article

References (68)

1. Arborelius L., Linner L., Wallsten C., Ahlenius S., and Svensson T.H. Partial 5-HT1A receptor agonist properties of (-)pindolol in combination with citalopram on serotonergic dorsal raphe cell firing in vivo. Psychopharmacology (Berl) 151 (2000) 77-84
2. Artigas F. 5-HT and antidepressants: new views from microdialysis studies. Trends Pharmacol Sci 14 (1993) 262
3. Artigas F., Perez V., and Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 51 (1994) 248-251
4. Artigas F., Romero L., de Montigny C., and Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 19 (1996) 378-383
5. Bakish D., Hooper C.L., Thornton M.D., Wiens A., Miller C.A., and Thibaudeau C.A. Fast onset: an open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy. Int Clin Psychopharmacol 12 (1997) 91-97
6. Baribeau J.C., and Laurent J.P. The effect of selective attention on augmenting/intensity function of the early negative waves of AEPs. Electroencephalogr Clin Neurophysiol Suppl 40 (1987) 68-75
7. Barton D.L., Loprinzi C.L., Novotny P., Shanafelt T., Sloan J., Wahner-Roedler D., et al. Pilot evaluation of citalopram for the relief of hot flashes. J Support Oncol 1 (2003) 47-51
8. Berman R.M., Darnell A.M., Miller H.L., Anand A., and Charney D.S. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 154 (1997) 37-43
9. Berman R.M., Anand A., Cappiello A., Miller H.L., Hu X.S., Oren D.A., et al. The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial. Biol Psychiatry 45 (1999) 1170-1177
10. Bhatti T., Gillin J.C., Seifritz E., Moore P., Clark C., Golshan S., et al. Effects of a tryptophan-free amino acid drink challenge on normal human sleep electroencephalogram and mood. Biol Psychiatry 43 (1998) 52-59
11. Blier P., and de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15 (1994) 220-226
12. Blier P., and Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 15 (1995) 217-222
13. Blier P., Bergeron R., and de Montigny C. Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response. Neuropsychopharmacology 16 (1997) 333-338
14. Bond A., and Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol 47 (1974) 211-218
15. Bordet R., Thomas P., and Dupuis B. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Reseau de Recherche et d'Experimentation Psychopharmacologique. Am J Psychiatry 155 (1998) 1346-1351
16. Buchsbaum M., Goodwin F., Murphy D., and Borge G. AER in affective disorders. Am J Psychiatry 128 (1971) 19-25
17. Carrillo-de-la-Pena M.T. Effects of intensity and order of stimuli presentation on AEPs: an analysis of the consistency of EP augmenting/reducing in the auditory modality. Clin Neurophysiol 110 (1999) 924-932
18. Clark B.J., Menninger K., and Bertholet A. Pindolol-the pharmacology of a partial agonist. Br J Clin Pharmacol 13 (1982) 149S-158S
19. Clifford E.M., Gartside S.E., Umbers V., Cowen P.J., Hajos M., and Sharp T. Electrophysiological and neurochemical evidence that pindolol has agonist properties at the 5-HT1A autoreceptor in vivo. Br J Pharmacol 124 (1998) 206-212
20. Corradetti R., Laaris N., Hanoun N., Laporte A.M., Le Poul E., Hamon M., et al. Antagonist properties of (-)-pindolol and WAY 100635 at somatodendritic and postsynaptic 5-HT1A receptors in the rat brain. Br J Pharmacol 123 (1998) 449-462
21. Croft R.J., and Barry R.J. EOG correction of blinks with saccade coefficients: a test and revision of the aligned-artefact average solution. Clin Neurophysiol 111 (2000) 444-451
22. Croft R.J., Klugman A., Baldeweg T., and Gruzelier J.H. Electrophysiological evidence of serotonergic impairment in long-term MDMA ("ecstasy") users. Am J Psychiatry 158 (2001) 1687-1692
23. Dawson L.A., and Nguyen H.Q. Effects of 5-HT1A receptor antagonists on fluoxetine-induced changes in extracellular serotonin concentrations in rat frontal cortex. Eur J Pharmacol 345 (1998) 41-46
24. Dreshfield L.J., Wong D.T., Perry K.W., and Engleman E.A. Enhancement of fluoxetine-dependent increase of extracellular serotonin (5-HT) levels by (-)-pindolol, an antagonist at 5-HT1A receptors. Neurochem Res 21 (1996) 557-562
25. Gallinat J., Bottlender R., Juckel G., Munke-Puchner A., Stotz G., Kuss H.J., et al. The loudness dependency of the auditory evoked N1/P2-component as a predictor of the acute SSRI response in depression. Psychopharmacology (Berl) 148 (2000) 404-411
26. Gallinat J., Senkowski D., Wernicke C., Juckel G., Becker I., Sander T., et al. Allelic variants of the functional promoter polymorphism of the human serotonin transporter gene is associated with auditory cortical stimulus processing. Neuropsychopharmacology 28 (2003) 530-532
27. Gartside S.E., Clifford E.M., Cowen P.J., and Sharp T. Effects of (-)-tertatolol, (-)-penbutolol and (+/-)-pindolol in combination with paroxetine on presynaptic 5-HT function: an in vivo microdialysis and electrophysiological study. Br J Pharmacol 127 (1999) 145-152
28. Hegerl U., Wulff H., and Muller-Oerlinghausen B. Intensity dependence of auditory evoked potentials and clinical response to prophylactic lithium medication: a replication study. Psych Res 44 (1992) 181-190
29. Hegerl U., Bottlender R., Gallinat J., Kuss H.J., Ackenheil M., and Moller H.J. The serotonin syndrome scale: first results on validity. Eur Arch Psychiatr Clin Neurosci 248 (1998) 96-103
30. Hegerl U., Gallinat J., and Juckel G. Event-related potentials. Do they reflect central serotonergic neurotransmission and do they predict clinical response to serotonin agonists?. J Affect Disord 62 (2001) 93-100
31. Hemels M.E., Koren G., and Einarson T.R. Increased use of antidepressants in Canada: 1981-2000. Ann Pharmacother 36 (2002) 1375-1379
32. Hensler J.G. Regulation of 5-HT1A receptor function in brain following agonist or antidepressant administration. Life Sci 72 (2003) 1665-1682
33. Hjorth S. (-)-Pindolol, but not buspirone, potentiates the citalopram-induced rise in extracellular 5-hydroxytryptamine. Eur J Pharmacol 303 (1996) 183-186
34. Hjorth S., and Sharp T. In vivo microdialysis evidence for central serotonin1A and serotonin1B autoreceptor blocking properties of the beta adrenoceptor antagonist (-)penbutolol. J Pharmacol Exp Ther 265 (1993) 707-712
35. Hughes J.M., Matrenza C., Kemp A.H., Harrison B.J., Liley D., and Nathan P.J. Selective effects of simultaneous monoamine depletion on mood and emotional responsiveness. Int J Neuropsychopharmacol 7 (2004) 9-17
36. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 9 Suppl 1 (1994) 19-26
37. Juckel G., Molnar M., Hegerl U., Csepe V., and Karmos G. Auditory-evoked potentials as indicator of brain serotonergic activity-first evidence in behaving cats. Biol Psychiatry 41 (1997) 1181-1195
38. Juckel G., Hegerl U., Molnar M., Csepe V., and Karmos G. Auditory evoked potentials reflect serotonergic neuronal activity-a study in behaving cats administered drugs acting on 5-HT1A autoreceptors in the dorsal raphe nucleus. Neuropsychopharmacology 21 (1999) 710-716
39. Juckel G., Mavrogiorgou P., Bredemeier S., Gallinat J., Frodl T., Schulz C., et al. Loudness dependence of primary auditory-cortex-evoked activity as predictor of therapeutic outcome to prophylactic lithium treatment in affective disorders-a retrospective study. Pharmacopsychiatry 37 (2004) 46-51
40. Kemp A.H., Gray M.A., Silberstein R.B., Armstrong S.M., and Nathan P.J. Augmentation of serotonin enhances pleasant and suppresses unpleasant cortical electrophysiological responses to visual emotional stimuli in humans. NeuroImage 22 (2004) 1084-1096
41. Lawrenson R.A., Tyrer F., Newson R.B., and Farmer R.D. The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared. J Affect Disord 59 (2000) 149-157
42. Leonard B.E. Pharmacology of new antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 8 (1984) 97-108
43. Martinez D., Hwang D., Mawlawi O., Slifstein M., Kent J., Simpson N., et al. Differential occupancy of somatodendritic and postsynaptic 5HT(1A) receptors by pindolol: a dose-occupancy study with [11C]WAY 100635 and positron emission tomography in humans. Neuropsychopharmacology 24 (2001) 209-229
44. Moreno F.A., Gelenberg A.J., Bachar K., and Delgado P.L. Pindolol augmentation of treatment-resistant depressed patients. J Clin Psychiatry 58 (1997) 437-439
45. Murphy D.L. Peripheral indices of central serotonin function in humans. Ann N Y Acad Sci 600 (1990) 282-295 discussion 295-6.
46. Nathan P.J., Segrave R., Phan K.L., O'Neil B., and Croft R.J. Direct Evidence that Acutely Enhancing Serotonin with the Selective Serotonin Reuptake Inhibitor Citalopram Modulates the Loudness Dependence of Auditory Evoked Potential (LDAEP) Maker of Central Serotonin Function. Human Psychopharm 21 1 (2006) 47-52
47. Newman-Tancredi A., Chaput C., Gavaudan S., Verriele L., and Millan M.J. Agonist and antagonist actions of (-)pindolol at recombinant, human serotonin1A (5-HT1A) receptors. Neuropsychopharmacology 18 (1998) 395-398
48. Paige S.R., Fitzpatrick D.F., Kline J.P., Balogh S.E., and Hendricks S.E. Event-related potential amplitude/intensity slopes predict response to antidepressants. Neuropsychobiology 30 (1994) 197-201
49. Perez V., Soler J., Puigdemont D., Alvarez E., and Artigas F. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius. Arch Gen Psychiatry 56 (1999) 375-379
50. Perez V., Puiigdemont D., Gilaberte I., Alvarez E., and Artigas F. Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors. J Clin Psychopharmacol 21 (2001) 36-45
51. Perry E.B., Berman R.M., Sanacora G., Anand A., Lynch-Colonese K., and Charney D.S. Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial. J Clin Psychiatry 65 (2004) 238-243
52. Rabiner E.A., Gunn R.N., Castro M.E., Sargent P.A., Cowen P.J., Koepp M.J., et al. beta-blocker binding to human 5-HT(1A) receptors in vivo and in vitro: implications for antidepressant therapy. Neuropsychopharmacology 23 (2000) 285-293
53. Rabiner E.A., Bhagwagar Z., Gunn R.N., Sargent P.A., Bench C.J., Cowen P.J., et al. Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. Am J Psychiatry 158 (2001) 2080-2082
54. Rabiner E.A., Bhagwagar Z., Gunn R.N., Cowen P.J., and Grasby P.M. Preferential 5-HT(1A) Autoreceptor Occupancy by Pindolol is Attenuated in Depressed Patients: Effect of Treatment or an Endophenotype of Depression?. Neuropsychopharmacology 29 9 (2004) 1688-1698
55. Romero L., Bel N., Artigas F., de Montigny C., and Blier P. Effect of pindolol on the function of pre- and postsynaptic 5-HT1A receptors: in vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacology 15 (1996) 349-360
56. Sclar D.A., Robinson L.M., Skaer T.L., Galin R.S. Trends in the prescribing of antidepressant pharmacotherapy: office-based visits, 1990-1995. Clinical Therapeutics 1998; 20: 871-84; 870
57. Segrave R., and Nathan P.J. Pindolol augmentation of selective serotonin reuptake inhibitors: accounting for the variability of results of placebo-controlled double-blind studies in patients with major depression. Hum Psychopharmacol 20 (2005) 163-174
58. Senkowski D., Linden M., Zubragel D., Bar T., and Gallinat J. Evidence for disturbed cortical signal processing and altered serotonergic neurotransmission in generalized anxiety disorder. Biol Psychiatry 53 (2003) 304-314
59. Simmons J.G., Allen N.B., Berger G., and Nathan P.J. The influence of chronic sertraline administration on the loudness dependence of the auditory evoked potential in healthy subjects. Psychophysiology 40 (2000) S80
60. Smeraldi E., Zanardi R., Benedetti F., Di Bella D., Perez J., and Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 3 (1998) 508-511
61. Sugrue M.F. Chronic antidepressant therapy and associated changes in central monoaminergic receptor functioning. Pharmacol Ther 21 (1983) 1-33
62. Tabachnick B.G., and Fidell L.S. Using multivariate statistics. 4th ed. (2001), Allyn & Bacon, Needham Heights
63. Tome M.B., Isaac M.T., Harte R., and Holland C. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 12 (1997) 81-89
64. Tuchtenhagen F., Daumann J., Norra C., Gobbele R., Becker S., Pelz S., et al. High intensity dependence of auditory evoked dipole source activity indicates decreased serotonergic activity in abstinent ecstasy (MDMA) users. Neuropsychopharmacology 22 (2000) 608-617
65. von Knorring L., and Perris C. Biochemistry of the augmenting-reducing response in visual evoked potentials. Neuropsychobiology 7 (1981) 1-8
66. Zanardi R., Artigas F., Franchini L., Sforzini L., Gasperini M., Smeraldi E., et al. How long should pindolol be associated with paroxetine to improve the antidepressant response?. J Clin Psychopharmacol 17 (1997) 446-450
67. Zanardi R., Franchini L., Gasperini M., Lucca A., Smeraldi E., and Perez J. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study. J Clin Psychopharmacol 18 (1998) 441-446
68. Zanardi R., Serretti A., Rossini D., Franchini L., Cusin C., Lattuada E., et al. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 50 (2001) 323-330